Minimum accelerometer wear-time for reliable estimates of physical activity and sedentary behaviour of people receiving haemodialysis by Prescott, Sean et al.
RESEARCH ARTICLE Open Access
Minimum accelerometer wear-time for
reliable estimates of physical activity and
sedentary behaviour of people receiving
haemodialysis
Sean Prescott1, Jamie P. Traynor2, Ilona Shilliday3, Tobia Zanotto1, Robert Rush1 and Thomas H. Mercer1*
Abstract
Background: Low levels of physical activity are implicated in low life expectancies of people receiving maintenance
haemodialysis. Accelerometers are increasingly being used to quantify activity behaviours of this population but guidance
to quality-assure such data is lacking. The objective of this study was to provide data processing and reduction
recommendations to ensure accelerometer-derived outcomes are sufficiently reliable for interpretative analysis.
Methods: Seventy people receiving maintenance haemodialysis (age 55.9 ± 15.7 years, 34% women, 23% diabetic)
from a single outpatient renal unit volunteered for the study. Participants wore Actigraph GT3x and ActivPAL
monitors during waking hours over seven days. Reliability of accelerometer output (normalised to wear-time) was
assessed via intraclass correlation coefficient (ICC). The Spearman-Brown prophecy formula was subsequently
applied to the ICCs to derive the minimum required accelerometer wear-time for each behavioural outcome.
Results: Monitor wear compliance was greater on dialysis compared to non-dialysis days (90% v 77%).
Participants were significantly more active on non-dialysis days compared to dialysis days but there were no
significant differences in estimated behaviours between days within the same condition. Average measure ICCs
for all accelerometer outcomes were high (range 0.76–0.96). Computations indicated that habitual physical
activity and sedentary behaviour could be estimated with a minimum reliability level of 0.80 from one dialysis
day and two non-dialysis days, and at least eight hours monitor wear per day. Applying this rubric allowed 90%
of participant data to be retained for further analysis.
Conclusions: Regardless of accelerometer, one dialysis and two non-dialysis days data with a minimum of eight
hours wear each day should enable habitual activity of people receiving maintenance haemodialysis to be
characterised with acceptable reliability. These recommendations reconcile the tension between wear-time
criteria stringency and retention of an adequately representative sample.
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Background
In the last two decades, a great number of studies have
consistently documented that low levels of physical ac-
tivity (PA) are highly prevalent among people receiving
maintenance haemodialysis (MHD) for established renal
failure (ERF) [1–5]. Large-scale epidemiological studies
suggest that 35 to 44% of this clinical population never
engage in any kind of structured PA, with 38 to 42% of
patients having severe limitations in performing moder-
ate PA [2, 3]. Interestingly, even higher proportions of
low PA seem to emerge from studies which employed
more objective measurements, such as accelerometry, as
about two thirds of people receiving MHD were cate-
gorised as either low active or sedentary [6, 7]. Import-
antly, sedentary behaviour in people with ERF is shaped
not only by high comorbidity levels and poor physical
function [8], but also by the fact that MHD entails pro-
longed periods of sedentary activity due to the imposed
sitting time during dialysis. Many studies have shown
that patients are less active during dialysis days com-
pared to non-dialysis days [9, 10]. The clinical implica-
tions of low PA levels involve multiple domains of
health. For instance, sedentary behaviour negatively af-
fects global physical function due to the well-known ad-
verse effects on bone and skeletal muscle function [8],
but also cardiovascular and mental health [11, 12]. Over-
all, low PA has been linked to lower quality of life as
well as to the development of adverse clinical outcomes
such as hospitalisations, major cardiovascular events and
mortality in people receiving MHD [2, 3, 12]. The World
Health Organisation target of a 10% relative reduction in
the prevalence of insufficient physical activity by 2025 to
reduce premature mortality indicates PA may shortly be
monitored alongside physiological health indices [13].
While patient-reported PA questionnaires are expedi-
ent, they have recognised limitations and accelerometers
are thus increasingly being adopted to objectively esti-
mate PA and sedentary behaviour. Importantly, acceler-
ometer derived outcomes are predictive of mortality,
physical function and associated with indices of health
status in the MHD population [4, 6, 7, 14–16]. However,
if accelerometer-based PA surveillance is to be routinely
employed in health management and research, then
stringent methodological criteria should govern its use.
A seven-day monitor wear period is typically prescribed
[6, 7, 17], but despite reminders and incentives, compli-
ance is often variable [18] with daily wear-time also sub-
ject to variation within and between participants [19].
The importance of minimum accelerometer-wear rec-
ommendations for reliable estimation of habitual PA has
been highlighted [20, 21]. Nonetheless, previous studies
using accelerometers to characterise PA of people re-
ceiving MHD have lacked methodological uniformity.
Number and type of days monitored are inconsistent,
often with no stated rationale, while more than 80% of
studies failed to define the number of wear hours re-
quired to constitute a valid day. Moreover, these studies
are remarkable for the fact that no participants were ex-
cluded from analyses due to insufficient monitor wear.
Thus, it would appear they have not explicitly at least,
taken into account the effects of discretionary wear on
accelerometer outcomes.
There is a trade-off between applying wear criteria that
are stringent enough to ensure data consistency while at
the same time facilitating retention of sample size that is
sufficiently representative and adequate for interpretative
analysis [19, 22, 23]. Guidance for accelerometer data re-
duction is available for asymptomatic adults [24–27], but
no equivalent methodological recommendations exist for
clinical populations like ERF, perhaps indicating low
awareness of their importance. In light of evidence link-
ing PA and sedentary time with health outcomes, there
is a pressing need to establish accelerometer data reduc-
tion guidelines for reliable estimation of these behav-
iours in ERF. The objectives of this study were to
determine the minimum accelerometer wear-time neces-
sary for reliable characterisation of habitual activity, and
the impact of wear criteria on sample retention. The aim
was to offer methodological recommendations to under-
pin quality assurance of future accelerometer-based
research in ERF.
Methods
Study design, setting and participants
This study conformed to the Declaration of Helsinki and
was approved by the West of Scotland Research Ethics
Service (REC reference number: 11/WS/0001). Seventy-
two self-selected individuals (55.9 ± 15.7 years) undergoing
maintenance HD therapy (thrice weekly) at Monklands
Hospital outpatient HD unit volunteered to take part in
this reliability study, which was conducted between
November 2011 and August 2013. Male or female indi-
viduals aged 18 years or over and able to ambulate a
minimum of 10 m (use of a walking aid was acceptable)
were considered eligible, while people with dementia or
severe cognitive impairment were excluded from par-
ticipation. Participant incentives were not used for this
research project. Written informed consent was ob-
tained from each participant.
Demographic and clinical characteristics
Participant demographics (age, gender, body mass index),
and clinical characteristics (biochemistry values, diagnosis
of diabetes, dialysis vintage and adequacy) were extracted
from the patients’ electronic medical records. Haemoglobin
(Hb) and albumin values were recorded from the closest
routine monthly bloods to the PA assessment (within the
nearest two-week period). Participants travelled to the
Prescott et al. BMC Nephrology          (2020) 21:230 Page 2 of 9
dialysis unit either by ambulance transport provided by the
hospital or by car.
Objective measurement of physical activity
Physical activity was estimated via Actigraph GT3x
(Actigraph Corp, Pensacola, Florida) and ActivPAL (PAL
Technologies Ltd., Glasgow) accelerometers, which were
positioned as per the manufacturers’ specifications on
the non-dominant hip and thigh respectively. The Acti-
graph GT3x records body accelerations within 0.05–0.2
units of gravity in three individual axes (vertical, hori-
zontal, perpendicular), with a sampling frequency of 30
Hz. The raw accelerometer data are then converted into
activity counts, with higher counts resulting from greater
or more frequent accelerations. Step-counts are calcu-
lated based on accelerometer data recorded on the verti-
cal axis only and are accumulated on a per-epoch basis.
The ActivPAL is a uniaxial accelerometer that records
posture outputs and step-counts from thigh inclination,
with a sampling frequency of 10 Hz. Time spent in dif-
ferent postures, transitions and step-counts are derived
via algorithms embedded in the ActivPAL software. Both
accelerometers were synchronised and initialised to col-
lect data over 15 s epochs [28] using the proprietary soft-
ware for each device installed on the same laptop.
Participants were instructed to wear the accelerometers
simultaneously during waking hours for 8 days and were
provided with a wear log.
Accelerometer data cleaning and categorisation
Participants were habituated to the accelerometers for a
day, which was excluded from subsequent analysis. The
monitoring period included three dialysis days, and four
non-dialysis days. Actigraph files were scrutinised for
spurious data (> 20,000 counts per minute (cpm)) and
wear-time was determined using a filter of 150 consecu-
tive zero-count minutes, with allowance for < 1 min of
activity counts < 100 cpm [29]. Data were inspected to
ensure dialysis sessions were not misclassified as non-
wear time. Actigraph files with > 18 h/day wear-time
suggested to be implausible [30] had logical waking
hours triangulated via ActivPAL data and the monitor
wear log. ActivPAL files were scrutinised for monitor
malfunctions using the PAL Technologies software. Data
were then exported to an Excel spreadsheet to enable ac-
curate determination of monitor wear (time between
first and last sit-to-stand transfers) and values for activity
behaviours.
All three Actigraph GT3x axes were enabled for PA
measurement. Sedentary time was determined via verti-
cal axis data using a uniaxial cutpoint of < 100 cpm [31],
with activity counts above this threshold categorised as
total PA. Time spent in moderate to vigorous physical
activity (MVPA) was categorised using a uniaxial cutpoint
of ≥1952 cpm [32]. ActivPAL estimated sitting/lying was
employed to indicate sedentary time in line with the
current definition for this behaviour [33]. ActivPAL total
PA was derived from time spent in standing activities, as
energy expenditure of postural skeletal muscle is above
the 1.5 metabolic equivalent of task (MET) threshold for
sedentary behaviour [33].
Data analysis
Reported Actigraph outcomes include: sedentary time;
total PA; MVPA; step-count; triaxial activity counts.
ActivPAL outcomes include: sit/lie time; standing time;
step-count; sit-to-stand transfers; energy expenditure.
All outcomes were normalised to daily wear-time to ad-
just for variation in discretionary wear [19]. Missing ac-
celerometer data due to loss to follow-up (n = 2, 2.8%)
were handled with listwise deletion method in the ana-
lysis, while missing accelerometer data arising from in-
complete compliance (range: n = 9, 12.5% to n = 28,
38.9%, as detailed in Fig. 1) were handled with pairwise
deletion. Data are presented as mean and standard devi-
ation (SD) or median and interquartile range (IQR) de-
pending on the underlying distribution. Condition effect
(i.e. dialysis versus non-dialysis days) on PA outcomes
was tested via paired t-test or Wilcoxon signed rank test.
Day effects within the same condition (i.e. dialysis days
only) were tested via repeated measures ANOVA or
Friedman’s test. Test significance level was set at p < .05.
Variability of accelerometer outcomes for dialysis and
non-dialysis days was assessed via intra-class correlation
coefficient (ICC) employing a two-way random effects
model (ICC 2,1). Non-normally distributed variables were
transformed for reliability calculations.
Calculation of required accelerometer wear-time
Minimum required wear was computed using the
Spearman-Brown prophecy formula [34], where ‘N’
equals the recommended number of wear days, ICCD is
the desired reliability level and ICCSM is the single meas-
ure of reliability. A reliability level of not less than 0.80
is recommended for physiological data [35]. The influ-
ence of longer daily wear and different levels of desired
reliability on required monitor wear was examined.
N ¼ ICCD 1‐ICCDð Þ½  1‐ICCSMð Þ ICCSM½ 
If computed wear days exceeded a whole number, the
required wear-time was rounded up to the next whole
number to ensure a minimum reliability criterion was
maintained. The impact of wear-time criteria on partici-
pant retention was also examined.
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Results
Figure 1 illustrates the data cleaning and participant in-
clusion process. Participant characteristics are presented
in Table 1. Age ranged from 24 to 87 years with women
making up one third of the sample, while diabetes preva-
lence was nearly one quarter. The mean prescribed time
on dialysis per session was 4 h. Biomarkers of health and
dialysis adequacy were within target ranges recom-
mended by the UK Renal Association.
Actigraph and ActivPAL wear compliance for the
seven-day monitoring period was 73 and 63% respect-
ively, with higher compliance observed for all three dia-
lysis days (90 and 79% respectively) compared to the
four non-dialysis days (77 and 67% respectively). Aver-
aged seven-day values for Actigraph and ActivPAL out-
come variables are presented in Table 2. Participants
were significantly more sedentary on dialysis days while
total PA and other activity indices were significantly
higher on non-dialysis days. No significant differences
were observed for accelerometer output variables among
days within the same condition (dialysis vs non-dialysis)
(Additional file 1: Table S1).
Average measure ICCs for accelerometer outcomes
ranged from 0.89 to 0.96 and 0.76 to 0.94 for Actigraph
and ActivPAL respectively (Additional file 1: Tables S2-
S5). Reliability of Actigraph outcomes remained consist-
ently high with longer monitor wear-time, while Activ-
PAL reliability on non-dialysis days tended to decline as
the number of participant datasets dropped below 45.
Computed wear-times for Actigraph and ActivPAL out-
comes are presented in Table 3. In general, the required
number of dialysis-days for each outcome declines as
the minimum amount of daily wear increases. Compara-
tively greater non-dialysis day wear is required.
Minimum required wear-time varied according to out-
come. One dialysis day and more than one but less than
two non-dialysis days were required for estimation of
sedentary behaviour and total PA, with a reliability level
of 0.80, from either accelerometer. A range of 1.12 to
1.16 dialysis and 0.87 to 0.97 non-dialysis days were
Fig. 1 Flowchart of accelerometer data cleaning and participant inclusion for reliability analysis
Table 1 Participant characteristics. [Mean ± SD, or Median (IQR)]
Total sample Males Females
n 70 46 24
Diabetes 16 (23%) 11 (24%) 5 (21%)
Age (years) 55.9 ± 15.7 58.8 ± 16.2 50.2 ± 13.3
BMI (kg/m2) 28.6 ± 6.4 28.0 ± 4.7 29.7 ± 8.8
Albumin (g/L) 39.0 (36.0–42.0) 39.5 (36.0–42.0) 39.0 (36.0–41.0)
Hb (g/dL) 11.3 ± 1.0 11.4 ± 1.0 11.0 ± 0.9
Dialysis adequacy (URR %) 71.0 (66.0–75.0) 69.0 (65.8–73.0) 75.0 (70.1–79.0)
Dialysis vintage (months) 15.8 (6.8–32.0) 17.2 (8.2–31.1) 9.4 (5.4–34.2)
BMI Body mass index; Hb Haemoglobin; URR Urea reduction ratio
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necessary for Actigraph estimates of MVPA. Actigraph
activity counts/minute and estimated steps/minute as
well as ActivPAL estimated energy expenditure required
0.59 to 0.89 dialysis days and 0.70 to 0.99 non-dialysis
days. A range of 1.12 to 1.5 days of each condition were
required for ActivPAL step-counts while a total of 4.84
to 6.02 days were necessary for sit-to-stand transfers.
Wear requirements were generally greater when data
were not normalised to accelerometer wear-time, and
more than doubled when reliability level was increased
to 0.90 (Additional file 1: Tables S6-S13).
Table 4 illustrates participant compliance with acceler-
ometer wear and retention according to one-hour incre-
ments of daily wear. Almost all participants returned
Actigraph and ActivPAL data containing a minimum of
one dialysis day and at least 84% wore the devices for
Table 2 Accelerometer derived outcomes. [Mean ± SD or Median (IQR)]
7 Days Dialysis Non-dialysis Dialysis v Non-dialysis
Actigraph GT3x (n = 51) (n = 63) (n = 54)
Wear time (min) 798.8 ± 103.1 863.7 ± 124.9 750.2 ± 111.8 t (50) = 11.40 p < 0.001
Sedentary (%) 83.4 ± 8.9 86.4 ± 6.6 81.2 ± 11.0 t (50) = 6.021 p < 0.001
Total PA (%) 16.6 ± 8.9 13.6 ± 6.6 18.8 ± 11.0 t (50) = − 6.021 p < 0.001
MVPA (%) 0.9 (0.3, 2.3) 0.7 (0.3, 1.4) 0.9 (0.2, 3.0) Z = − 3.21 p = 0.001
Steps/day 2303 (1048, 3876) 1935 (959, 2666) 2370 (1115, 4391) Z = − 3.05 p = 0.002
Steps/min 2.8 (1.5, 5.0) 2.2 (1.4, 3.6) 3.3 (1.5, 5.4) Z = − 4.04 p < 0.001
Triaxial cpm 303 (176, 397) 233(151, 327) 322 (203, 473) Z = − 5.54 p < 0.001
ActivPAL (n = 44) (n = 55) (n = 47)
Wear (min) 801.7 ± 107.6 856.51 ± 134.8 745.05 ± 124.0 t (43) = 5.565 p < 0.001
Sit/Lie (%) 74.89 ± 12.07† 81.7 ± 9.5 70.0 ± 15.9 t (43) = 6.046 p < 0.001
Stand (%) 25.1 ± 12.1 18.3 ± 9.5 30.0 ± 15.9 t (43) = − 6.047 p < 0.001
Transitions/hour 2.6 ± 0.8 2.1 ± 0.7 2.9 ± 1.0 t (43) = − 7.568 p < 0.001
Steps/day 3242 (1909, 4615) 2189 (1493, 3577) 3594 (2055, 5854) Z = − 3.769 p < 0.001
Steps/min 4.2 (2.5, 6.1) 2.76 (1.8, 3.7) 4.9 (2.6, 8.3) Z = − 4.621 p < 0.001
EE (METs/min) 1.37 (1.33, 1.42) 1.34 (1.31, 1.36) 1.40 (1.33, 1.49) Z = − 4.831 p < 0.001
MVPA Moderate to vigorous physical activity; EE Energy expenditure; cpm Counts per minute
Table 3 Computed minimum wear-time requirements for Actigraph and ActivPAL outcomes on dialysis days and non-dialysis days
with a reliability level of 0.80
Actigraph
Sedentary % Total PA % MVPA% Steps/min Triaxial counts/min
Wear/day Dialysis Non-dialysis Dialysis Non-dialysis Dialysis Non-dialysis Dialysis Non-dialysis Dialysis Non-dialysis
≥6 h 1.15 1.21 1.15 1.21 1.12 0.93 0.64 0.71 0.89 0.77
≥7 h 0.99 1.16 0.99 1.16 1.16 0.87 0.61 0.71 0.81 0.76
≥8 h 0.98 1.35 0.98 1.35 1.12 0.89 0.60 0.85 0.80 0.87
≥9 h 1.00 1.38 1.00 1.38 1.14 0.95 0.60 0.84 0.80 0.87
≥10 h 0.96 1.97 0.96 1.97 1.14 0.97 0.59 0.87 0.77 0.99
ActivPAL
Sit/lie time % Stand time % Transfers/hour Steps/min Energy MET/min
Wear/day Dialysis Non-dialysis Dialysis Non-dialysis Dialysis Non-dialysis Dialysis Non-dialysis Dialysis Non-dialysis
≥6 h 0.80 1.93 0.80 1.93 2.76 2.06 1.15 1.19 0.83 0.83
≥7 h 0.79 1.93 0.79 1.93 2.90 2.06 1.12 1.19 0.82 0.82
≥8 h 0.79 2.27 0.79 2.27 2.90 2.03 1.12 1.35 0.82 0.82
≥9 h 0.83 2.54 0.83 2.54 3.03 2.46 1.25 1.41 0.85 0.85
≥10 h 0.72 1.99 0.72 1.99 2.88 3.14 1.21 1.50 0.70 0.70
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two non-dialysis days. The proportion of participants
retained declines as the required wear per day increases,
and is governed largely by individuals returning suffi-
cient non-dialysis day wear. The majority of participants
(94%) were retained if the Spearman-Brown derived
minimum-wear recommendations are applied.
Discussion
This is the first study to provide comprehensive wear-time
guidance for reliable estimation of activity of people re-
ceiving MHD. Wear-time requirements varied according
to outcome, but overall, it appears that regardless of which
accelerometer is employed, a minimum of any one dialysis
and two non-dialysis days wear should provide reliable es-
timates of habitual PA and sedentary behaviour. The clin-
ical characteristics of the study sample are similar to those
of the wider Scottish MHD population [36]. The median
age was younger than that of the whole dialysis unit (56
versus 64 years) and Scottish HD population [36] but simi-
lar to previous motion-sensor based PA studies involving
people receiving MHD [6, 7, 16, 37].
Wear-time recommendations made here for total PA
are in line with previous studies employing older uni-
axial Actigraphs. Hart et al. [26] observed 3 days of Acti-
graph wear provided similar reliability for total PA
estimates in a sample of 52 asymptomatic older adults
(69.3 ± 7.4 years). Three to 4 days and four to 5 days of
accelerometer wear has been recommended for healthy
older adults [24] and young to middle-aged rural and
urban adults [25] respectively. The discrepancy between
these studies and the present study may be due in part
to the former employing a higher total PA cutpoint (>
500 cpm). Higher wear requirements reported by Cook
and Lambert [25] may also reflect greater variability of
daily PA for younger adults. In contrast, people receiving
MHD effectively have their activity clamped on dialysis
days thereby limiting intra-day variability. In addition,
reliability analyses in the cited studies were performed
on minutes of total PA, and thus ignored the potential
effects of inter- and intra-individual variation in discretion-
ary wear on accelerometer output. This may also explain
why the required wear-time for sedentary behaviour pro-
posed here (3 days) is lower than the five to 7 days recom-
mended in previous studies [24–26]. Computed wear-time
requirements for minutes of sedentary time in the present
study were similarly high at six to 7 days (Additional file 1:
Tables S10-S13) due to lower reliability.
In our study, reliable Actigraph triaxial activity count
output was obtained from just 2 days wear. Similarly, a
study simulating triaxial accelerometry using three
Caltrac devices produced comparable reliability (0.83)
from 2 days data in a smaller sample of 30 asymptomatic
young men [38]. Coleman and Epstein [39], reported
three to 4 days of wear gave acceptable levels of general-
isability for Tri-Trac-3D activity count output of young,
low-active men. Overall, required wear-time for triaxial
activity counts in the present study is consistent with
two to 3 days reported for middle-aged to older adults
using older uniaxial Actigraphs [24, 25, 40]. Three days
of Actigraph wear were necessary for reliable estimation
of MVPA, the type of activity associated with a health
enhancing effect. This is in agreement with Matthews
et al. [24] who recommended three to 4 days wear for
healthy middle-aged adults. Four to 5 days was recom-
mended for younger rural and urban adults by Cook and
Lambert [25], a difference possibly mediated in part by
MVPA often being planned and less variable for older
adults [41], who made up a large proportion of the
present sample.
To the best of our knowledge, only two reliability
studies examined the minimum wear requirements for
the ActivPAL monitor. The recommendations made by
these studies, which were conducted in asymptomatic
adolescent females [42] and adults [43], seem to partially
contrast with our findings. Particularly, Dowd et al., [42]
concluded that at least 12 days of accelerometer wear
would be required to estimate sedentary behaviour in a
female population, aged 13–18 years-old, with the same
level of reliability used in the present study (ICC ≥ 0.8).
On the other hand, Aguilar-Farias et al., [43] reported
that, in order to reliably estimate PA and sedentary be-
haviour in a group of asymptomatic adults (mean age =
39.1 ± 12.4 years; ICC ≥ 0.8), at least 5 days of ActivPAL
wear would be needed. The apparent discrepancies be-
tween these findings and the observations emerging
from our study are almost certainly ascribable to the dif-
ferent populations examined. Specifically, we take the
view that older age, comorbidities and lower levels of
functional independence may be responsible for the
lower inter- and intra-individual variability in PA behav-
iours exhibited by our study participants.
Table 4 Number (and %) of participants retained according to minimum daily wear-time and required number of wear days
Wear time criteria ≥6 h ≥7 h ≥8 h ≥9 h ≥10 h
Actigraph Activpal Actigraph Activpal Actigraph Activpal Actigraph Activpal Actigraph Activpal
Dialysis days ≥1 70 (100) 69 (98.6) 70 (100) 69 (98.6) 70 (100) 69 (98.6) 70 (100) 68 (97.1) 70 (100) 68 (97.1)
Non-dialysis days ≥2 66 (94.3) 66 (94.3) 65 (92.9) 66 (94.3) 63 (90) 64 (91.4) 63 (90) 62 (88.6) 61 (87.1) 59 (84.3)
Participants retained 66 (94.3) 66 (94.3) 65 (92.9) 66 (94.3) 63 (90) 64 (91.4) 63 (90) 61 (87.1) 61 (87.1) 59 (84.3)
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Step-counts are often used as a motivational outcome
[19] and have previously been employed in ERF [37], how-
ever recommended wear-time has not previously been ex-
amined for accelerometers with this output. Minimum
required accelerometer wear for steps/minute and steps/
day was two to 4 days in our study, which is consistent
with previous research evaluating pedometer reliability
during free-living conditions. Any 2 days of pedometer
wear were recommended by Rowe et al. [41] for senior
adults (74.0 ± 9.5 years), while three to 4 days were re-
quired for asymptomatic middle-aged [44] and older
adults [26] respectively. In contrast, Kang et al. [45] rec-
ommended up to 6 days, a disparity which may be due to
much younger participant age (38 ± 9.9 years) and season-
ality increasing step-count variability in their study.
Indices of PA were significantly higher on non-dialysis
days compared to dialysis days, which is in agreement
with earlier research [9, 10]. High average measure ICCs
and no observed significant differences between days
within the same condition (Additional file 1: Table S1)
suggest the inclusion of ‘weekend’ wear is not compulsory.
This finding is consistent with previous studies showing
no additional improvement in accelerometer outcome re-
liability with weekend data inclusion for adults [46, 47].
Guidance regarding hours of accelerometer wear per
day is crucial to determine which days may be included
for subsequent analyses, as minimum daily wear-time
impacts PA outcomes of participants and sample size
retention [20, 23]. These data suggest that including days
with as few as 6 h wear-time does not appear to ad-
versely affect accelerometer outcome reliability. On bal-
ance however, a minimum standard of 8 h to ‘rule in’ a
valid day is recommended as more appropriate due to
the amount of time occupied by MHD and the variation
in PA patterns around this event [15]. Previous studies
have similarly concluded wear thresholds of six to 8 h
per day facilitate acceptable reliability for PA estimation
of children [48, 49]. This recommendation contrasts
with the commonly employed standard of 10 h/day ad-
vocated by Troiano et al. [50]. However, the latter was
adopted from research examining sample size retention
according to different wear-time algorithms [20] and not
reliability analyses.
Obviously, using the 10-h benchmark increases the
ability to compare findings, but this wear criterion may
not be feasible for everyone receiving MHD, a clinical
population beset with high prevalence of multi-morbidity,
condition-related symptoms, low PA and advanced aver-
age age. Moreover, the amount of daily wear-time appears
to be less influential on PA outcomes in low-active popu-
lations, but significantly impacts sample size retention
[51]. The rubric suggested here (one dialysis and two non-
dialysis days, 8 hours/day wear) would allow 90% of our
sample to be included for final analyses, and is comparable
to the 93% retention rate reported by Chen et al. [27] who
employed similar data reduction criteria for low-active in-
dividuals. Importantly, applying the ≥10 h/day criterion
would reduce the present sample size by three to 7 %
without an appreciable increase in reliability and possibly
introduce a source of bias.
Minimum wear recommendations are necessary for
PA data quality assurance so that the ability to detect re-
lationships with other variables is not diminished and
conclusions drawn are not limited [18]. Moreover, reli-
able characterisation of PA is crucial for comparison
with previous research, as well as for monitoring pur-
poses to stratify health risk, and detect PA behaviour
change. Interestingly, Actigraph data revealed only 13%
of our sample met recommended levels of MVPA for a
health enhancing effect, however, 92% regularly achieved
a threshold of 50 min of total daily PA, which is inde-
pendently associated with improved survival in ERF [4].
It should also be acknowledged that, since low self-
reported PA is one of the main determinants of physical
frailty, a highly prevalent syndrome in MHD patients
[52], accelerometers may offer a more objective charac-
terisation of PA levels to more accurately track PA
changes that could be indicative of frailty over time. In
other words, accelerometers providing a detailed classifi-
cation of activity intensities (e.g. MVPA vs total PA) and
behaviours (e.g. step-counts, number of sit-to-stand
transfers), such as the ones used in this study, may be
useful for early detection and prevention of frailty in this
clinical population. The wear-time recommendations in
the present study are proposed with the caveat that they
are the minimum requirement only to achieve an ac-
ceptable level of reliability. Adhering to a criterion of 7
days would endow accelerometer outcomes with super-
ior reliability. However, applying such a standard with
a ≥ 10 h/day wear criterion would exclude more than half
of our Actigraph and ActivPAL datasets, as observed in
previous studies [53, 54], seriously compromising statis-
tical power and sample representativeness. Wear-time
recommendations made here therefore balance the need
for acceptable reliability while retaining an adequate
sample size and preserving external validity. These rec-
ommendations may shape future study design, by short-
ening monitoring protocols, and help clinicians who are
engaged in PA counselling to minimise patient burden
and expedite data collection required for PA monitoring.
However, potential bias of such purposive sampling
should first be explored.
Limitations
Reliability coefficients for some accelerometer outcomes
declined as required daily wear increased reflecting the
limitations of a reduced sample size. Consequently, re-
quired wear-time for a given daily wear threshold was
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greater for ActivPAL compared to Actigraph, particularly
on non-dialysis days when the sample size was less than
the minimum of 50 recommended for reliability analysis
[55]. Wear-time recommendations for some ActivPAL
outcomes are therefore based on the assumption that reli-
ability coefficients would be higher with a larger sample
size as observed for Actigraph, and may warrant verifica-
tion in a larger cohort. In addition, it should be acknowl-
edged that the relatively young age of participants in our
study (56 years) may reflect the exclusion of patients with
higher frailty levels. For instance, those who were bed-
bound or with severe cognitive impairment were not
eligible to participate. Therefore, the generalisability of
our study findings to the general ERF population on dialy-
sis may be affected.
Conclusions
High wear compliance observed here indicates that rou-
tine PA surveillance via accelerometry is feasible for
people receiving MHD. Dialysis days are characterized
by greater physical inactivity, but across days within the
same condition activity behaviours are stable. Regardless
of accelerometer used, a minimum of any one dialysis
and two non-dialysis days with at least 8 h/day wear
should provide reliable estimates of PA and sedentary
behaviour. These recommendations resolve the tension
between scientific rigour and retention of an adequately
representative sample size.
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